Clinical Efficacy Endpoints from the Phase 3 CANOPY Study Evaluating[...]
Pharmacokinetics and Serum Virus Neutralizing Antibody Titers Following[...]
Results from a Phase 1 First in human Study of Pemivibart: an[...]
04/28/2022 | Press release | Distributed by Public on 04/27/2022 22:43
Please select the service you want to use:
Smartlinks | OM Holdings Limited | Finance | Metals Markets | Stock Markets | Security Markets | Commodities | Stock Markets | Security Markets | Company News | Manufacturing | Metals | Iron and Steel | Non-Ferrous Metals | Metals Markets | Logistics, Freight and Courier Services | Transportation | Public Companies | Mining and Exploration Companies | Australian Securities Exchange (ASX) | Börse Stuttgart | OTC Markets | Chi-X Australia | Cboe Off Exchange
Copyright ©2006-2024 Public Technologies Inc. | Privacy Policy | Terms of Use | Contact